| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO SE SI SK SM TR |
|
Designated Extension States: |
|
AL BA ME RS |
| (30) |
Priority: |
10.04.2009 US 16841109 P
|
| (43) |
Date of publication of application: |
|
24.07.2019 Bulletin 2019/30 |
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
15159780.4 / 2930184 |
|
10712681.5 / 2417158 |
| (73) |
Proprietor: ELI LILLY AND COMPANY |
|
Indianapolis, IN 46285 (US) |
|
| (72) |
Inventors: |
|
- Chedid, Marcio
Indianapolis, IN 46206-6288 (US)
- Darling, Ryan James
Indianapolis, IN 46206-6288 (US)
- Galvin, Rachelle Jeanette
Indianapolis, IN 46206-6288 (US)
- Swanson, Barbara Anne
Indianapolis, IN 46206-6288 (US)
|
| (74) |
Representative: Kent, Lindsey Ruth |
|
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU
Bracknell, Berkshire RG12 1PU (GB) |
| (56) |
References cited: :
WO-A1-2008/097510
WO-A2-2006/015373
|
WO-A1-2010/129752
WO-A2-2007/084344
|
|
| |
|
|
- FULCINITI MARIATERESA ET AL: "Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent
for multiple myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, UNITED STATES LNKD-
DOI:10.1182/BLOOD-2008-11-191577, vol. 114, no. 2, 9 July 2009 (2009-07-09), pages
371-379, XP009134332, ISSN: 1528-0020 [retrieved on 2009-05-05]
- GAVRIATOPOULOU MARIA ET AL: "Dickkopf-1: a suitable target for the management of myeloma
bone disease.", EXPERT OPINION ON THERAPEUTIC TARGETS JUL 2009 LNKD- PUBMED:19530987,
vol. 13, no. 7, July 2009 (2009-07), pages 839-848, XP009134320, ISSN: 1744-7631
- YACCOBY SHMUEL ET AL: "Antibody-based inhibition of DKK1 suppresses tumor-induced
bone resorption and multiple myeloma growth in vivo", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY,
US LNKD- DOI:10.1182/BLOOD-2006-09-047712, vol. 109, no. 5, 1 March 2007 (2007-03-01)
, pages 2106-2111, XP002486200, ISSN: 0006-4971 [retrieved on 2006-10-26]
- ETTENBERG SETH A ET AL: "BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits
tumor-induced osteolytic bone disease", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN
ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01),
page 947, XP009134334, ISSN: 0197-016X
- HEATH DEBORAH J ET AL: "Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation
and prevents the development of osteolytic bone disease in multiple myeloma", JOURNAL
OF BONE AND MINERAL RESEARCH, AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, NEW
YORK, NY, US LNKD- DOI:10.1359/JBMR.081104, vol. 24, no. 3, 1 March 2009 (2009-03-01),
pages 425-436, XP009134333, ISSN: 0884-0431 [retrieved on 2009-12-04]
- FILIPPO CARACI ET AL: "The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment
of Neurodegenerative Disorders", NEUROCHEMICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM
PUBLISHERS, NE LNKD- DOI:10.1007/S11064-008-9710-0, vol. 33, no. 12, 22 April 2008
(2008-04-22), pages 2401-2406, XP019647587, ISSN: 1573-6903
- HALL CHRISTOPHER L ET AL: "Dickkopf-1 expression increases early in prostate cancer
development and decreases during progression from primary tumor to metastasis", PROSTATE,
WILEY-LISS, NEW YORK, NY, US LNKD- DOI:10.1002/PROS.20805, vol. 68, no. 13, 15 September
2008 (2008-09-15), pages 1396-1404, XP009134318, ISSN: 0270-4137 [retrieved on 2008-06-16]
- TERPOS E: "Antibodies to dickkopf-1 protein", EXPERT OPINION ON THERAPEUTIC PATENTS,
INFORMA HEALTHCARE, GB LNKD- DOI:10.1517/13543776.16.10.1453, vol. 16, no. 10, 1 October
2006 (2006-10-01), pages 1453-1458, XP002486202, ISSN: 1354-3776
- ZHOU XIAO-LEI ET AL: "Downregulation of Dickkopf-1 is responsible for high proliferation
of breast cancer cells via losing control of Wnt/beta-catenin signaling", ACTA PHARMACOLOGICA
SINICA, vol. 31, no. 2, February 2010 (2010-02), pages 202-210, XP009134321,
- KRAJ MARIA: "Multiple myeloma bone disease and novel anti-myeloma agents", ACTA HAEMATOLOGICA
POLONICA, vol. 39, no. 2, 2008, pages 163-178, XP009134337, ISSN: 0001-5814
- DIARRA DANIELLE ET AL: "Dickkopf-1 is a master regulator of joint remodeling", NATURE
MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM1538, vol.
13, no. 2, 1 February 2007 (2007-02-01), pages 156-163, XP002486201, ISSN: 1078-8956
[retrieved on 2007-01-21]
- MELODY MAZON ET AL: "Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?",
CANCERS, vol. 8, no. 7, 28 June 2016 (2016-06-28), page 62, XP55329263, DOI: 10.3390/cancers8070062
|
|
